Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18875 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Sergei I Obydennyi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia. Hauptthemen laut MEDLINE: Wiskott-Aldrich Syndrome, Thrombocytopenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Wiskott–Aldrich syndrome (WAS) is an X‐linked recessive disorder caused by WAS gene mutations resulting in haematopoietic/immune cell defects. Recent studies report accelerated death of WAS platelets and lymphocytes. Data on megakaryocyte (MK) maturation, viability and their possible role in thrombocytopenia development in WAS are limited. In this study we evaluate the MK viability and morphology in untreated, romiplostim‐treated WAS patients compared with normal controls. The study included 32 WAS patients and 17 healthy donors. MKs were captured from bone marrow aspirates by surface‐immobilized anti‐GPIIb‐IIIa antibody. Viability (by phosphatidylserine [PS] externalization), distribution by maturation stages and size of MK were determined by light microscopy. MK distribution by maturation stages in patients differed from controls. 40 ± 22% of WAS MKs versus 23 ± 11% of normal MKs were at maturation stage 3 ( p = 0.02), whereas 24 ± 20% in WAS and 39 ± 14% in controls had megakaryoblast morphology ( p = 0.05). Romiplostim treatment changed the MK maturation stages distribution close to normal. PS‐positive (PS+) MK in WAS was significantly higher (21 ± 21%) than in healthy controls (2 ± 4%, p < 0.01). WAS patients with more damaging truncating mutations and higher disease score had higher PS+ MK fraction (Spearman r = 0.6, p < 0.003). We conclude that WAS MKs have increased cell death tendency and changes in maturation pattern. Both could contribute to thrombocytopenia in WAS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia.
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
- Institute of Experimental Cardiology, National Medical Research Center for Cardiology, Russian Ministry of Health, Moscow, Russia.
- Faculty of Physics, Moscow State University, Moscow, Russia.
ORCID-Profile: Sergei I Obydennyi, Sofya A Kuznetsova, Anna Khoreva, Alexey A Maschan
Förderung
- Russian Science Foundation
Zitieren
APA
Obydennyi, S. I., Kuznetsova, S. A., Fedyanina, O. S., Khoreva, A., Voronin, K., Mazurov, A. V., Glukhova, A. A., Artemenko, E. O., Ataullakhanov, F. I., Maschan, A. A., Novichkova, G. A., Shcherbina, A., & Panteleev, M. A. (2023). Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients. British Journal of Haematology. https://doi.org/10.1111/bjh.18875
Vancouver
Obydennyi SI, Kuznetsova SA, Fedyanina OS, Khoreva A, Voronin K, Mazurov AV, et al. Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients. British Journal of Haematology. 2023. doi:10.1111/bjh.18875
BibTeX
@article{Obydennyi2023,
author = {Obydennyi, Sergei I and Kuznetsova, Sofya A and Fedyanina, Olga S and Khoreva, Anna and Voronin, Kirill and Mazurov, Alexey V and Glukhova, Anna A and Artemenko, Elena O and Ataullakhanov, Fazoil I and Maschan, Alexey A and Novichkova, Galina A and Shcherbina, Anna and Panteleev, Mikhail A},
title = {Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18875}
}
EUVIMED